Iron therapy in chronic kidney disease: Recent changes, benefits and risks

Blood Reviews

Volumn 30, Issue 1, 2016, Pages 65-72

  Ribeiro, Sandra ^a   Belo, Luís ^a   Reis, Flávio ^b,c   Santos Silva, Alice ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anemia; Chronic kidney disease; Hemodialysis; Intravenous iron; Iron overload; Iron therapy; Mortality

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; IRON; TRANSFERRIN; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ALLERGIC REACTION; ANEMIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SAFETY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; INFECTION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ANEMIA, IRON-DEFICIENCY; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DOSE CALCULATION; DRUG EFFECTS; HEMODIALYSIS; KIDNEY; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ANEMIA, IRON-DEFICIENCY; DRUG DOSAGE CALCULATIONS; EPOETIN ALFA; ERYTHROPOIETIN; FERRITINS; HEMATINICS; HUMANS; IRON; IRON OVERLOAD; KIDNEY; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSFERRIN;

EID: 84960312577     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.07.006     Document Type: Article

References (87)

1. Stauffer M.E., Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014, 9:e84943.
2. Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica 1998, 83:724-732.
3. Nangaku M., Eckardt K.U. Pathogenesis of renal anemia. Semin Nephrol 2006, 26:261-268.
4. Costa E., Lima M., Alves J.M., Rocha S., Rocha-Pereira P., Castro E., et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008, 28:268-275.
5. Costa E., Rocha S., Rocha-Pereira P., Nascimento H., Castro E., Miranda V., et al. Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 2008, 28:935-940.
6. do Sameiro-Faria M., Ribeiro S., Costa E., Mendonca D., Teixeira L., Rocha-Pereira P., et al. Risk factors for mortality in hemodialysis patients: two-year follow-up study. Dis Markers 2013, 35:791-798.
7. Pereira R., Costa E., Goncalves M., Miranda V., do Sameiro Faria M., Quintanilha A., et al. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodial Int 2010, 14:295-301.
8. Ribeiro S., do Sameiro Faria M., Mascarenhas-Melo F., Freitas I., Mendonca M.I., Nascimento H., et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol 2012, 36:317-323.
9. do Sameiro Faria M., Ribeiro S., Rocha-Pereira P., Miranda V., Quintanilha A., Reis F., et al. Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients. J Vasc Access 2013, 14:335-341.
10. Łukaszyk E., Łukaszyk M., Koc-Z˙órawska E., Tobolczyk J., Bodzenta-Łukaszyk A., Małyszko J. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Kidney Blood Press Res 2015, 40:366-373.
11. Costa E., Swinkels D.W., Laarakkers C.M., Rocha-Pereira P., Rocha S., Reis F., et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009, 122:226-229.
12. Preza G.C., Pinon R., Ganz T., Nemeth E. Cellular catabolism of the iron-regulatory peptide hormone hepcidin. PLoS One 2013, 8:e58934.
13. Zhang A.S. Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Adv Nutr 2010, 1:38-45.
14. Canavesi E., Alfieri C., Pelusi S., Valenti L. Hepcidin and HFE protein: iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 2012, 1:166-176.
15. Finberg K.E. Unraveling mechanisms regulating systemic iron homeostasis. Hematology Am Soc Hematol Educ Program 2011, 2011:532-537.
16. Tanno T., Porayette P., Sripichai O., Noh S.J., Byrnes C., Bhupatiraju A., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009, 114:181-186.
17. Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014, 46:678-684.
18. Ibrahim H.N., Ishani A., Guo H., Gilbertson D.T. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. Nephrol Dial Transplant 2009, 24:3138-3143.
19. Summary of product characteristics European Medicines Agency 2008, [Available at http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124, accessed on 09/04/2015].
20. Horl W.H. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013, 73:117-130.
21. Green J.M., Leu K., Worth A., Mortensen R.B., Martinez D.K., Schatz P.J., et al. Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events. Exp Hematol 2012, 40:575-587.
22. Finkelstein F.O., Story K., Firanek C., Mendelssohn D., Barre P., Takano T., et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:33-38.
23. Gouva C., Nikolopoulos P., Ioannidis J.P., Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004, 66:753-760.
24. Disease K. Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012, 2:279-335.
25. Kuwahara M., Mandai S., Kasagi Y., Kusaka K., Tanaka T., Shikuma S., et al. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease. Clin Exp Nephrol 2014, 10.1007/s10157-014-1023-9.
26. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. National Kidney Foundation; 2002 [Available at /, accessed on 19/04/2015]. http://www.kidney.org.
27. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
28. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
29. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
30. McMurray J.J., Uno H., Jarolim P., Desai A.S., de Zeeuw D., Eckardt K.U., et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J 2011, 162:748-755. e3.
31. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
32. Important safety advisory on procrit, aranesp and epogen 2007, Food and Drug Administration, [Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=516, accessed on 19/04/2015].
33. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease Food and Drug Admnistration 2011, [Available at http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm, accessed on 19/04/2015].
34. Locatelli F., Aljama P., Canaud B., Covic A., De Francisco A., Macdougall I.C., et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010, 25:2846-2850.
35. Charytan C., Qunibi W., Bailie G.R. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005, 100:c55-c62.
36. Qunibi W.Y., Martinez C., Smith M., Benjamin J., Mangione A., Roger S.D. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011, 26:1599-1607.
37. Van Wyck D.B., Roppolo M., Martinez C.O., Mazey R.M., McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005, 68:2846-2856.
38. Rampton D., Folkersen J., Fishbane S., Hedenus M., Howaldt S., Locatelli F., et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014, 99:1671-1676.
39. Stoves J., Inglis H., Newstead C.G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001, 16:967-974.
40. Macdougall I.C., Bock A.H., Carrera F., Eckardt K.U., Gaillard C., Van Wyck D., et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014, 29:2075-2084.
41. Agarwal A.K., Silver M.R., Reed J.E., Dhingra R.K., Liu W., Varma N., et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006, 260:577-585.
42. Mercadel L., Metzger M., Haymann J.P., Thervet E., Boffa J.J., Flamant M., et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014, 9:e99781.
43. Zanen A.L., Adriaansen H.J., van Bommel E.F., Posthuma R., Th de Jong G.M. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 1996, 11:820-824.
44. Pai A.B., Boyd A.V., McQuade C.R., Harford A., Norenberg J.P., Zager P.G. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007, 27:343-350.
45. Pai A.B., Conner T., McQuade C.R., Olp J., Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011, 24:603-613.
46. Stefansson B.V., Haraldsson B., Nilsson U. Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 2011, 118:c249-c256.
47. Pisani A., Riccio E., Sabbatini M., Andreucci M., Del Rio A., Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 2014, 30:645-652.
48. Toblli J.E., Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther 2014, 8:2475-2491.
49. Ferrari P., Kulkarni H., Dheda S., Betti S., Harrison C., St Pierre T.G., et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:77-83.
50. Wood J.C. Estimating tissue iron burden: current status and future prospects. Br J Haematol 2015, 170:15-28.
51. Bailie G.R., Larkina M., Goodkin D.A., Li Y., Pisoni R.L., Bieber B., et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013, 28:2570-2579.
52. Canavese C., Bergamo D., Ciccone G., Longo F., Fop F., Thea A., et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004, 65:1091-1098.
53. Ghoti H., Rachmilewitz E.A., Simon-Lopez R., Gaber R., Katzir Z., Konen E., et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012, 89:87-93.
54. Rostoker G., Griuncelli M., Loridon C., Couprie R., Benmaadi A., Bounhiol C., et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012, 125:991-999.
55. Feldman H.I., Santanna J., Guo W., Furst H., Franklin E., Joffe M., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002, 13:734-744.
56. Feldman H.I., Joffe M., Robinson B., Knauss J., Cizman B., Guo W., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004, 15:1623-1632.
57. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3070-3080.
58. Kshirsagar A.V., Freburger J.K., Ellis A.R., Wang L., Winkelmayer W.C., Brookhart M.A. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013, 8:e78930.
59. Zitt E., Sturm G., Kronenberg F., Neyer U., Knoll F., Lhotta K., et al. Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS One 2014, 9:e114144.
60. Bailie G.R., Larkina M., Goodkin D.A., Li Y., Pisoni R.L., Bieber B., et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015, 87:162-168.
61. UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients European Medicines Agency 2013, [Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB, accessed on 19/04/2015].
62. Salahudeen A.K., Oliver B., Bower J.D., Roberts L.J. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001, 60:1525-1531.
63. Tovbin D., Mazor D., Vorobiov M., Chaimovitz C., Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002, 40:1005-1012.
64. Oberg B.P., McMenamin E., Lucas F.L., McMonagle E., Morrow J., Ikizler T.A., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65:1009-1016.
65. Dounousi E., Papavasiliou E., Makedou A., Ioannou K., Katopodis K.P., Tselepis A., et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006, 48:752-760.
66. Kao M.P., Ang D.S., Pall A., Struthers A.D. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010, 24:1-8.
67. Pawlak K., Domaniewski T., Mysliwiec M., Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009, 204:309-314.
68. Hambali Z., Ahmad Z., Arab S., Khazaai H. Oxidative stress and its association with cardiovascular disease in chronic renal failure patients. Indian J Nephrol 2011, 21:21-25.
69. Reis K.A., Guz G., Ozdemir H., Erten Y., Atalay V., Bicik Z., et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005, 46:255-264.
70. Minqin R., Watt F., Huat B.T., Halliwell B. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic Biol Med 2003, 34:746-752.
71. Rajendran R., Minqin R., Ronald J.A., Rutt B.K., Halliwell B., Watt F. Does iron inhibit calcification during atherosclerosis?. Free Radic Biol Med 2012, 53:1675-1679.
72. Kuo K.L., Hung S.C., Lee T.S., Tarng D.C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014, 25:2596-2606.
73. Toblli J.E., Cao G., Angerosa M. Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations. Int J Cardiol 2015, 187:196-197.
74. Shah S.V., Baliga R., Rajapurkar M., Fonseca V.A. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007, 18:16-28.
75. Morita T., Nakano D., Kitada K., Morimoto S., Ichihara A., Hitomi H., et al. Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney. Eur J Pharmacol 2015, 756:85-91.
76. Naito Y., Fujii A., Sawada H., Oboshi M., Iwasaku T., Okuhara Y., et al. Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease. Hypertens Res 2015, 38:463-470.
77. Naito Y., Sawada H., Oboshi M., Fujii A., Hirotani S., Iwasaku T., et al. Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats. PLoS One 2013, 8:e75906.
78. Garrido P., Ribeiro S., Fernandes J., Vala H., Bronze-da-Rocha E., Rocha-Pereira P., et al. Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model. PLoS One 2015, 10:e0124048.
79. Patruta S.I., Horl W.H. Iron and infection. Kidney Int Suppl 1999, 69:S125-S130.
80. Canziani M.E., Yumiya S.T., Rangel E.B., Manfredi S.R., Neto M.C., Draibe S.A. Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment. Artif Organs 2001, 25:866-869.
81. Teehan G.S., Bahdouch D., Ruthazer R., Balakrishnan V.S., Snydman D.R., Jaber B.L. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004, 38:1090-1094.
82. Brewster U.C., Coca S.G., Reilly R.F., Perazella M.A. Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) 2005, 10:124-128.
83. Bansal A., Sandhu G., Gupta I., Kalahalli S., Nayak R., Zouain E., et al. Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis. Am J Ther 2014, 21:250-253.
84. Brookhart M.A., Freburger J.K., Ellis A.R., Wang L., Winkelmayer W.C., Kshirsagar A.V. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013, 24:1151-1158.
85. Kuragano T., Matsumura O., Matsuda A., Hara T., Kiyomoto H., Murata T., et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014, 86:845-854.
86. Miskulin D.C., Tangri N., Bandeen-Roche K., Zhou J., McDermott A., Meyer K.B., et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014, 9:1930-1939.
87. Sirken G., Raja R., Rizkala A.R. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol 2006, 66:348-356.